The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The SOUNDTRACK-E trial: investigating AZD0486 in CLL, MCL, and DLBCL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, introduces the SOUNDTRACK-E trial (NCT06564038), a Phase I/II dose-escalation study of a novel bispecific antibody, AZD0486, with three sub-studies. This agent targets CD19 and CD3, and its safety and efficacy are being evaluated in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, SOUNDTRACK-E is investigating a new bispecific antibody called AZD0486, which is targeting CD19 and CD3. This is a little bit different from some of the commonly now approved bispecific antibodies that target CD20. We think CD19 is a particularly attractive target in CLL because of its ubiquitous expression at high levels. And we’re optimistic based on some early data from follicular lymphoma that this agent will be very active but also very well tolerated with relatively low rates of cytokine release syndrome and neurologic toxicities...
So, SOUNDTRACK-E is investigating a new bispecific antibody called AZD0486, which is targeting CD19 and CD3. This is a little bit different from some of the commonly now approved bispecific antibodies that target CD20. We think CD19 is a particularly attractive target in CLL because of its ubiquitous expression at high levels. And we’re optimistic based on some early data from follicular lymphoma that this agent will be very active but also very well tolerated with relatively low rates of cytokine release syndrome and neurologic toxicities. So SOUNDTRACK-E is the first study of this drug in patients with CLL as well as mantle cell lymphoma. It’s also a study that looks at subcutaneous dosing of the compound compared to prior IV dosing, which would be very convenient for patients. And so we’re starting with very low dose with a dose ramp up to try to mitigate CRS and other toxicities. There’s also a cohort of this study looking at the combination of the AZD0486 with R-CHOP chemotherapy for patients with diffuse large B-cell lymphoma as a frontline therapy. So this is a trial in progress poster, really just summarizing the design of the study, which is ongoing now, and we’re excited to be actively recruiting patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting: AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Galapagos, Genentech, Genmab, Janssen, Merck, MEI Pharma, Nuvalent, Schrödinger; Research Support: Ascentage, AstraZeneca, MEI Pharma, Novartis.
